Metformin Does Not Increase UTI Risk
Based on the most authoritative evidence available, metformin does not increase the risk of urinary tract infections (UTIs). In fact, recent high-quality research demonstrates that metformin may actually reduce mortality associated with UTIs in patients with type 2 diabetes.
Key Evidence
Metformin's Safety Profile
The most recent American Diabetes Association guidelines (2025) and FDA drug labeling comprehensively detail metformin's side effects, and UTI is notably absent from the list of recognized adverse effects 1, 2. The principal side effects are:
- Gastrointestinal intolerance (bloating, abdominal discomfort, diarrhea)
- Lactic acidosis (rare, primarily with eGFR <30 mL/min/1.73 m²)
- Vitamin B12 deficiency
- Worsening neuropathy symptoms
Research Evidence Shows No Increased UTI Risk
A 2022 large-scale propensity score-matched study of 40,774 patients with type 2 diabetes found that metformin use showed no significant difference in UTI risk compared to non-users (adjusted HR 1.06,95% CI 0.98-1.15) 3. Importantly, this same study demonstrated that metformin was associated with a 58% reduction in death due to UTI or sepsis (aHR 0.58,95% CI 0.42-0.8), with longer cumulative duration of use showing even greater protective effects.
A 2016 Danish nationwide study of 131,949 patients initiating diabetes therapy found virtually no difference in community-based antibiotic use between metformin initiators and other glucose-lowering drugs 4.
The Real Culprits: SGLT2 Inhibitors and Other Medications
When UTIs occur in diabetic patients, the evidence points to other medications:
- SGLT2 inhibitors (like dapagliflozin, empagliflozin) are consistently associated with increased genital tract infections and candida UTIs due to glucosuria 5, 6, 7
- A 2025 observational study found that metformin ranked 4th among newly prescribed medications before UTI events, but this was based on prescription frequency, not causation 8
- The same study showed opioids, statins, and PPIs were more commonly prescribed before UTI events than SGLT2 inhibitors
Clinical Implications
Continue metformin without concern for UTI risk. The medication's established benefits—reducing microvascular complications, cardiovascular events, and death—far outweigh any theoretical concerns 1.
Important Caveats:
- Patients with diabetes have inherently higher UTI risk due to their underlying condition, not metformin
- If a patient on metformin develops recurrent UTIs, investigate other causes: poor glycemic control, anatomical abnormalities, or concomitant SGLT2 inhibitor use
- Do not discontinue metformin for UTI concerns unless contraindicated for other reasons (eGFR <30, lactic acidosis risk factors)
When to Suspect Other Medications:
If UTIs develop after starting diabetes therapy, consider: